気管支拡張症薬の世界市場2019-2023

◆英語タイトル:Global Bronchiectasis Drugs Market 2019-2023
◆商品コード:IRTNTR31722
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年7月20日
◆ページ数:131
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、気管支拡張症薬の世界市場について調べ、気管支拡張症薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、気管支拡張症薬の市場規模をセグメンテーション別(製品別(抗生物質、去痰薬、その他の薬)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は気管支拡張症薬の世界市場規模が2019-2023期間中に年平均5%成長すると予測しています。
・サマリー
・レポートの範囲
・気管支拡張症薬の市場状況
・気管支拡張症薬の市場規模
・気管支拡張症薬の市場予測
・気管支拡張症薬の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(抗生物質、去痰薬、その他の薬)
・気管支拡張症薬の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Bronchiectasis Drugs Market: About this market

Bronchiectasis drugs include antibiotics, expectorants, and others. Technavio’s bronchiectasis drugs market analysis considers sales from the antibiotics, expectorants, and other drugs segments. Our analysis also considers the sales of bronchiectasis drugs in Asia, Europe, North America, and ROW. In 2018, the antibiotics segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the increasing prevalence of respiratory tract infections and the easy availability of low-cost drugs will significantly help the antibiotics segment in maintaining its leading market position. Also, our global bronchiectasis drugs report has observed market growth factors such as increasing cases of associated risk factors, availability of low-cost off-label generics, and surge in the geriatric population. However, lack of approved drugs for bronchiectasis, underdiagnosis of bronchiectasis, and preference for substitute treatment options may hamper the growth of the bronchiectasis drugs industry over the forecast period.

Global Bronchiectasis Drugs Market: Overview

Availability of low-cost off-label generics

The strong prevalence of bronchiectasis is prompting vendors to capitalize on the trend and release low-priced off label generics into the market. This trend is prevalent in developed and underdeveloped countries. Also, there have been recent approvals of low-cost generic drugs. Therefore, the easy availability of low-cost off-label generics will increase sales of vendors, propelling the growth of the market. The global bronchiectasis drugs market will record a CAGR of almost 5% during the forecast period.

Advances in the diagnostics of respiratory diseases

The rising incidence of respiratory conditions such as bronchiectasis is increasing the need for advanced diagnostic techniques. As a result, technologies such as high-resolution computed tomography are gaining popularity to screen respiratory indications. The use of advanced diagnostic techniques will help medical pulmonologists, pathologists, and other specialists in determining the stage of the condition, which will help in administering appropriate medication. Therefore, this trend will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global bronchiectasis drugs market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global bronchiectasis drugs market is fragmented. Technavio’s robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading bronchiectasis drugs manufacturers, which include Endo International Plc, GlaxoSmithKline Plc, Neopharma LLC, Pfizer Inc., and Reckitt Benckiser Group Plc.

Also, the bronchiectasis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Antibiotics – Market size and forecast 2018-2023

Expectorants – Market size and forecast 2018-2023

Other drugs – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Growing awareness about bronchiectasis

Advances in the diagnostics of respiratory diseases

Strategic alliances

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Endo International Plc

GlaxoSmithKline Plc

Neopharma LLC

Pfizer Inc.

Reckitt Benckiser Group Plc

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Product – Market share 2018-2023 (%)

Exhibit 19: Comparison by product

Exhibit 20: Antibiotics – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Antibiotics – Year-over-year growth 2019-2023 (%)

Exhibit 22: Expectorants – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Expectorants – Year-over-year growth 2019-2023 (%)

Exhibit 24: Other drugs – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Other drugs – Year-over-year growth 2019-2023 (%)

Exhibit 26: Market opportunity by product

Exhibit 27: Customer landscape

Exhibit 28: Market share by geography 2018-2023 (%)

Exhibit 29: Geographic comparison

Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: North America – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in North America

Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Europe

Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 38: Percentage of geriatric population in Asia 2007 and 2017

Exhibit 39: Top 3 countries in Asia

Exhibit 40: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 41: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 42: Top 3 countries in ROW

Exhibit 43: Key leading countries

Exhibit 44: Market opportunity

Exhibit 45: Cost comparison of brand and generic drugs

Exhibit 46: Growth in geriatric population 2013-2017 (%)

Exhibit 47: Alternative therapies for bronchiectasis treatment

Exhibit 48: Impact of drivers and challenges

Exhibit 49: Vendor landscape

Exhibit 50: Landscape disruption

Exhibit 51: Vendors covered

Exhibit 52: Vendor classification

Exhibit 53: Market positioning of vendors

Exhibit 54: Endo International Plc – Vendor overview

Exhibit 55: Endo International Plc – Business segments

Exhibit 56: Endo International Plc – Organizational developments

Exhibit 57: Endo International Plc – Geographic focus

Exhibit 58: Endo International Plc – Segment focus

Exhibit 59: Endo International Plc – Key offerings

Exhibit 60: Endo International Plc – Key customers

Exhibit 61: GlaxoSmithKline Plc – Vendor overview

Exhibit 62: GlaxoSmithKline Plc – Business segments

Exhibit 63: GlaxoSmithKline Plc – Organizational developments

Exhibit 64: GlaxoSmithKline Plc – Geographic focus

Exhibit 65: GlaxoSmithKline Plc – Segment focus

Exhibit 66: GlaxoSmithKline Plc – Key offerings

Exhibit 67: GlaxoSmithKline Plc – Key customers

Exhibit 68: Neopharma LLC – Vendor overview

Exhibit 69: Neopharma LLC – Business segments

Exhibit 70: Neopharma LLC – Organizational developments

Exhibit 71: Neopharma LLC – Key offerings

Exhibit 72: Neopharma LLC – Key customers

Exhibit 73: Pfizer Inc. – Vendor overview

Exhibit 74: Pfizer Inc. – Business segments

Exhibit 75: Pfizer Inc. – Organizational developments

Exhibit 76: Pfizer Inc. – Geographic focus

Exhibit 77: Pfizer Inc. – Segment focus

Exhibit 78: Pfizer Inc. – Key offerings

Exhibit 79: Pfizer Inc. – Key customers

Exhibit 80: Reckitt Benckiser Group Plc – Vendor overview

Exhibit 81: Reckitt Benckiser Group Plc – Business segments

Exhibit 82: Reckitt Benckiser Group Plc – Organizational developments

Exhibit 83: Reckitt Benckiser Group Plc – Geographic focus

Exhibit 84: Reckitt Benckiser Group Plc – Segment focus

Exhibit 85: Reckitt Benckiser Group Plc – Key offerings

Exhibit 86: Reckitt Benckiser Group Plc – Key customers

Exhibit 87: Validation techniques employed for market sizing

Exhibit 88: Definition of market positioning of vendors



【掲載企業】

Endo International Plc, GlaxoSmithKline Plc, Neopharma LLC, Pfizer Inc., and Reckitt Benckiser Group Plc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[気管支拡張症薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆